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Abstract
Inflammation is generally a temporary and limited condition but may lead to a chronic 
one if immune and physiological homeostasis are disrupted. The autonomic nervous 
system has an important role in the short- and, also, long-term regulation of homeostasis 
and, thus, on inflammation. Autonomic modulation in acute and chronic inflammation 
has been implicated with a sympathetic interference in the earlier stages of the inflam-
matory process and the activation of the vagal inflammatory reflex to regulate innate 
immune responses and cytokine functional effects in longer processes. The present 
review focuses on the autonomic mechanisms controlling proinflammatory responses, 
and we will discuss novel therapeutic options linked to autonomic modulation for dis-
eases associated with a chronic inflammatory condition such as sepsis.
Keywords: inflammation, autonomic nervous system, heart rate variability,  
anti-inflammatory pathway, inflammatory reflex, sepsis
1. Introduction
Inflammation is the physiological response to invading pathogens and tissue damage, such as 
exposure to extreme heat or cold, ischemia, and trauma [1, 2]. The inflammatory response can 
be divided into acute or chronic inflammation. An acute inflammatory response is a controlled 
process, with a short time window of minutes up to a few hours and it is characterized by the 
abundant presence of a specific type of immune competent cells (neutrophils), responsible for 
clearing invading pathogens and promote tissue repair, thus restoring homeostasis. However, 
uncontrolled inflammation, which extends from days up to years, may cause more severe com-
plications. In the latter, if an accumulation of lymphocytes in the inflamed tissue predominates, 
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both immune and physiological homeostasis are disrupted, thereby the inflammation can prog-
ress to a chronic condition [1, 2]. In its most severe form, it can lead to permanent tissue damage, 
organ dysfunction, and, ultimately, death [3]. The immune cells residing in tissues, i.e., macro-
phages, fibroblasts, mast cells, and dendritic cells, as well as circulating leukocytes, including 
monocytes and neutrophils, recognize pathogen invasion and/or cell damage with intracellular 
or surface-expressed pattern recognition receptors (PRRs). These receptors detect, either directly 
or indirectly, pathogen-associated molecular patterns (PAMPs), such as, microbial nucleic acids, 
lipoproteins, and carbohydrates, often essential for microbe survival, or damage-associated 
molecular patterns (DAMPs), endogenous molecules normally found in cells, that are released 
during necrosis contributing to sterile inflammation. Activated PRRs in response to PAMPs and 
DAMPs, oligomerize and assemble large multisubunit factors, such as, nuclear factor kappa 
B (NF-kB), activator protein 1 (AP1), cellular transcription factor (CREB), CCAAT-enhancer-
binding proteins (c/EBP), and interferon regulatory factors (IRF) transcription factors, which 
will in turn initiate complex downstream signaling cascades, resulting in the increased expres-
sion of key pro- and anti-inflammatory genes [2, 3]. For instance, protease caspase-1, activated 
by a subset of PRRs, causes maturation of cytokines interleukins IL-1b and IL-18.
Expression of genes encoding enzymes, chemokines, cytokines, adhesion molecules, and 
regulators of the extracellular matrix promotes the further recruitment and activation of leu-
kocytes to the region, which are crucial for eliminating foreign particles and host debris [2, 3]. 
Cell adhesion molecules and chemokines facilitate leukocyte extravasation from the circula-
tion to the affected site, the chemokines stimulating G-protein-coupled receptors (GPCRs) 
[3]. Thus, the immune system plays a crucial and defining role in the overall inflammatory 
response processes through recruitment of various immune cell types, in addition to the 
release of pro-inflammatory cytokines into the bloodstream, including interleukin 1 (IL-1), 
interleukin 6 (IL-6), and tumor necrosis factor alpha (TNFα), which are inhibited by media-
tors of inflammation resolution, such as anti-inflammatory cytokines, that restore cellular 
homeostasis and defend the organism from external injuries [2].
The interaction between nervous and immune systems, or the “supersystems” as described by 
Tada [4], is, in fact, critical in the maintenance and regulation of homeostasis, not only under a 
daily routine, but also, in adverse environmental conditions caused by injury, infections, and 
exposure to toxins [5–7]. Indeed, the autonomic nervous system controls the inflammatory 
processes and immune responses, by finding a balance between pro-inflammatory and anti-
inflammatory responses, ensuring an adequate host defense with minimal collateral damage 
due to overly aggressive responses of the innate immune system [6]. Both parasympathetic 
and sympathetic efferent nerves have been suggested to affect immune cells and inflamma-
tory responses. The latter interfere in the earlier stages of the inflammatory process, while 
the parasympathetic nervous system is important to regulate innate immune responses and 
cytokine functional effects in chronic processes [6, 8, 9].
2. Autonomic nervous system and inflammation
Over the last few years, association between inflammation and common human diseases (e.g., 
sepsis, obesity, diabetes, rheumatoid arthritis) remains an unsolved mystery of current biol-
ogy and medicine [10–13]. Inflammation as a response to infection interacts with different 
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parts of the nervous system. Indeed, recent studies indicate that systemic inflammation can 
be attenuated by the autonomic nerve fibers [14].
The autonomic nervous system (ANS) includes the sympathetic and parasympathetic ner-
vous system (SNS and PNS, respectively) as its motor systems, and regulates and integrates 
many human physiological systems and functions, such as the cardiovascular system, the 
endocrine and exocrine systems, and the digestive system [14, 15]. As reviewed by Kenney 
and Ganta, to balance the functions of autonomic effector organs, the SNS and PNS work 
antagonistically, synergistically, or independently [14]. Previous studies have shown that 
both the SNS and PNS can sense inflammation and influence development and severity of 
inflammatory processes in animal models [12, 16].
There are many chronic autoimmune diseases in which there is an imbalance of the ANS, for 
example, rheumatoid arthritis (RA), caused by synovial inflammation, leading to bone ero-
sions, cartilage damage, and ultimately joint deformities and disability [8, 12]. Patients with 
RA have autonomic modifications, with lower parasympathetic activity and less frequently, 
alterations in sympathetic function [17]. These alterations are correlated with higher levels 
of inflammatory markers, such as C-reactive protein (CRP) concentrations and erythrocyte 
sedimentation rate [17, 18]. Another example is obesity, which consists in the accumulation 
of abnormal and excessive fat that may interfere with the maintenance of an optimal state of 
health and is accompanied by an increased morbidity and mortality [19]. This condition is 
generally associated with other clinical comorbidities including, cardiovascular impairment, 
atherosclerosis, insulin resistance, and diabetes mellitus [19, 20]. The excess of macronutrients 
in the adipose tissues stimulates them to release inflammatory mediators (TNFα, Il-6) and 
reduces production of adiponectin, predisposing to a pro-inflammatory state and oxidative 
stress [20]. The ANS has a significant role in the integrated short-term regulation of weight, 
modulating the satiety signal and energy expenditure. The afferent vagal pathways are prob-
ably the most important link between the gut and the brain and interact in a complex way 
with gut hormones. SNS has the physiological function of increasing lipolysis and energy 
expenditure, through sympathetic innervation in white and brown adipose tissues. However, 
in obesity, SNS activity is compromised and might trigger alterations in sympathetic regula-
tion of cardiovascular function, thus favoring the development of cardiovascular complica-
tions, such as hypertension [21, 22] and organ dysfunction [23, 24].
Another two examples of immune/inflammatory diseases are sepsis and severe burn injury, both 
characterized by severe global changes to the entire immune system [25]. The immunopatho-
logical response to the intense disruptions to the body’s homeostatic balance can contribute to 
the development of systemic inflammatory response syndrome (SIRS), serious metabolic dis-
turbances, and subsequent multiple organ failure and death [25, 26]. During the acute phase, 
following burn injury, there is an increase in sympathetic activity, which is important for the 
modulation of energy substrate mobilization, cardiovascular, and hemodynamic compensation 
and wound repair [27]. Nevertheless, prolonged or excessive sympathetic activity due to the acti-
vation of positive feedback mechanism can also be deleterious [27]. Furthermore, the increased 
susceptibility to infection and other systemic disorders are also accompanied by excessive inflam-
matory responses that underline the observed cardiac dysfunction, acute respiratory distress 
syndrome, acute renal failure, increased intestinal permeability resulting in bacterial transloca-
tion, hypermetabolism, hypercatabolism, and ultimately, sepsis [28, 29]. Sepsis can, therefore, be 
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an associated comorbidity of burn injuries, but in its essence is a highly common heterogeneous 
syndrome in the general population and will be further reviewed in Section 3 [25].
2.1. The role of sympathetic nervous system in the inflammatory processes
The sympathetic nervous system (SNS) is responsible for the “fight-or-flight” response to 
threatening situations and consists of neural hardwiring emanating from the spinal cord to 
innervate target organs, including primary and secondary lymphoid organs. About 25% of 
sympathetic nerve fibers arise from cranial nerves III, VII, and IX and from the second and 
third sacral spinal nerves [30]. Diverse stimuli (stressors, cytokines, and infection) trigger 
the SNS and consequent catecholamine release, inducing functional alterations in immune 
system susceptibility to respond to an invasive infection and other pathologies. As previ-
ously mentioned, the SNS interacts in several different manners with the immune system 
to maintain immune homeostasis under basal conditions, by enhancing host defenses to 
eliminate pathogens, promoting healing after tissue injury, and restoring homeostasis after 
pathogen elimination and/or tissue repair. This communication with all immune competent 
cells occurs directly by stimulated release of its major neurotransmitter, i.e., norepineph-
rine—NE, and subsequent intercellular signaling via postsynaptic adrenergic receptors 
(ARs) expressed in closely apposed immunocytes, i.e., T and B lymphocytes, antigen-
presenting cells, stromal cells, granulocytes, macrophages, and mast cells [15]. The SNS is 
highly adaptive, and to appropriately regulate the immune system, it acts through the:
1. Constant up- and down-regulation of diverse target cell functions across time (i.e., expan-
sion, differentiation, apoptosis, and cytokine secretion) and
2. Detection and interaction with the diverse signaling pathways that mediate the above cel-
lular functions [14].
In the initial stages of the inflammatory processes, the body assumes an “inflammatory con-
figuration” with increased systemic SNS and hypothalamic-pituitary-adrenal (HPA) axis activ-
ity through the chemoreceptor reflex, the ultimate protective, which can be interpreted as an 
“energy appeal reaction,” resulting in the provision of enough energy-rich fuels, like glucose and 
free fatty acids, to fulfill the needs of an activated immune system together with the maintenance 
of appropriate oxygen blood levels. If inflammation evolves to a more severe state, the system 
changes into a “chronic inflammatory condition,” that, according to Pongratz and Straub, is char-
acterized by an increased systemic activity of the SNS, an increased activity of the HPA axis but 
without immunosuppression (glucocorticoid receptor desensitization and inadequacy), and a 
local repulsion of SNS fibers from inflamed tissue, including lymphoid organs, to create zones 
of permitted inflammation [8]. The immune response is more or less uncoupled from central 
regulation to avoid the anti-inflammatory influence of the brain. All mechanisms ensure an opti-
mal fight against an invading antigen. Nevertheless, if a prolonged or inappropriate activation 
of either the SNS or immune system persists, the effects are detrimental and can result in the 
collapse of these two systems, ultimately failing in re-establishing immune system homeostasis 
within normal physiological ranges [8, 15]. Under such conditions, the immune system and/or 
SNS can promote pathological and lethal effects, including chronic inflammation, toxic shock, 
tissue damage, immune deficiency, autoimmunity, and cancer [15], as well as, cachexia, high 
blood pressure, insulin resistance, leading to increased levels of cardiovascular mortality [8].
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Several studies have demonstrated the role of the SNS in inflammation. Martelli et al. showed 
that in a rat model of intravenous endotoxin, a bilateral section of splenic sympathetic nerves 
deeply increases inflammatory cytokine release; however, bilateral vagotomy was ineffective, 
which suggests a splanchnic sympathetic efferent reflex arc of the anti-inflammatory neural 
pathway [31]. Another clinical phenomenon is immunosuppression after stroke [32]. Indeed, 
the 6-hydroxydopamine, which blocks a nonselective α-adrenoreceptor and causes phar-
macological ablation of the SNS, may also attenuate stroke-induced immunological abnor-
malities, prevent infections, and improve the survival, and thus SNS activation, instead of 
the PNS, has a significant role in the immunosuppression response [6, 32–34]. Additionally, 
in hypertensive patients, the central inhibition of the SNS decreased peripheral TNF serum 
levels [35]. Moreover, del Rey and colleagues have also found in an animal model of arthri-
tis that during protracted inflammation, there might be a disruption of this communication 
between the brain and the immune system [36]. There are also several studies indicating that 
the sympathetic nervous system might be influencing different forms of cancer [37]. In fact, 
epidemiological studies showed that breast cancer and melanoma improve with the use of 
beta-blockers, while other studies imply that psychological stress might modulate SNS activ-
ity, with a significant impact on inflammation and consequently on the pathogenesis of some 
cancers [37, 38].
Finally, recent studies show that the SNS plays a significant role in several immune-mediated 
or immune-related diseases, including sepsis [39], colitis [40], allergic asthma [41], chronic eye 
inflammation [42], arthritis [8, 36], among others.
2.2. The role of parasympathetic nervous system in the inflammatory processes
The parasympathetic nervous system (PSNS) innervates multiple organ systems, including 
cardiovascular, respiratory, immune, and endocrine systems [43] and plays a critical role in 
a diverse array of physiological processes, such as inflammation, immune response, heart 
rate, gastrointestinal peristalsis, and digestion [13]. About 75% of parasympathetic innerva-
tion comes from the tenth cranial nerve, the vagus nerve (VN), that extends throughout the 
body, and is the largest nerve and main parasympathetic division of the autonomic nervous 
system [13, 30, 44]. Vagus nerve comprises both sensory afferent neurons, crucial for conduct-
ing peripheral immune signals to the brain, which integrate the visceral sensory information 
and coordinates the autonomic function and visceral activity [13, 33, 34], and motor efferent 
neurons, which integrate the information that was delivered to the central nervous system 
and control the peripheral effectors [30, 45]. The vagus nerve not only regulates gut physiol-
ogy but also mediates cholinergic anti-inflammatory pathway, the inflammatory reflex that 
controls immune function, and pro-inflammatory responses during infection and injury 
[35, 45, 46]. The sensory afferent vagus nerve fibers detect peripheral inflammatory mediators, 
such as cytokines, released by activated macrophages and other immune cells, revealing its 
pro-inflammatory properties; however, a potent anti-inflammatory effect is exhibited by the 
efferent branch [46]. The animal models of acute inflammation reveal that the activation of 
the efferent vagus nerve, probably due to binding of acetylcholine on the alpha-7 subunit-
containing nicotinic receptors (α7nAChR), essential for the vagal anti-inflammatory action 
[47, 48] resulted in reduced systemic production of pro-inflammatory cytokines [46, 49]. This 
suggests that in the initial phase of inflammation processes, the neuroimmune path eliminates 
the infectious agent, and in the posterior phase re-establishes the homeostasis [13, 33, 34, 50].
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In human studies, the parasympathetic neurotransmitter acetylcholine attenuated proinflam-
matory cytokine release (e.g., TNFα) in lipopolysaccharide-stimulated macrophage cultures 
[49], so nicotine was more effective than muscarine in inhibiting TNF release. Human macro-
phages express α7nAChR subunit, and its knockdown makes macrophages less responsive to 
nicotine-mediated TNF inhibition [49].
Activating efferent vagus nerve can significantly suppress systemic pro-inflammatory cyto-
kine levels in endotoxemia animal models, as the acetylcholine (Ach) released from the nerve 
terminals binds to the α7n-AChR expressed on macrophages, to modulate the immune sys-
tem response [51]. α7nAChR, expressed in the nervous and immune systems, is important for 
mediating anti-inflammatory signaling by inhibiting NF-κB nuclear translocation and activat-
ing the JAK2/STAT3 pathway [48, 49, 51], being also a crucial neural component connect-
ing the parasympathetic vagus nerve with the sympathetic splenic nerve at the mesenteric 
ganglion [52]. The endotoxemia animal model reveals that peripheral vagal afferents can be 
activated by responding directly to bacterial lipopolysaccharide (LPS) and cytokines, such as 
TNFα, interleukin-1 (IL-1), interleukin-6 (IL-6), and interferon-gamma (IFN-γ). IL-1 receptors, 
expressed on vagal afferents, can be activated by inflammatory stimulation to regulate the 
immune responses [23, 48]. It has been shown that an excess of proinflammatory cytokine was 
released in α7nAChR knockout mice, and macrophages from these animals fail to respond 
to cholinergic agonists [6, 48]. Further, electrical vagus nerve stimulation reduced systemic 
TNFα concentrations and prevented septic shock in rats [49], and in mice, the vagus nerve 
stimulation (VNS), as well as splenic nerve electrical stimulation, inhibits lipopolysaccharide 
(LPS)-induced TNFα release [49, 50, 52, 53]; however, those results were quite surprising 
because the spleen does not have vagal innervation [53].
Several experiments demonstrated that the sympathetic splenic nerve connects the vagus nerve 
to the spleen [47, 52]. It is possible that the α7nAchR regulates both the neuronal connection and 
the macrophage activation. Moreover, the connection between the vagus and splenic nerves has 
been a matter of constant debate [43]. For example, anatomical and physiological studies have 
demonstrated no connection between the vagus and splenic nerves [54]. Additionally, denerva-
tion of the arterial splenic nerve in mice led to the inhibition of the cholinergic anti-inflammatory 
pathway [52]. To resolve this inhibition is essential to find a non-neural link in the anti-inflammatory 
pathway from vagus to spleen. Some authors have proposed an unconventional and theoretical 
model, where vagus nerve stimulation activates multiple cell types, the choline acetyltransfer-
ase positive (CHAT+), epithelial cells, endothelial cells, muscle fibers, and immune cells (such 
as lymphocytes and macrophages) that are not resident in the spleen, migrating in direction 
of this organ and subsequently releasing acetylcholine [12, 46, 55]. This electrical nerve stimu-
lation therapy could be applied concomitantly with a pharmacological treatment for a better 
response. The human studies reveal that the great advantage of this model is the stimulation of 
ACh/norepinephrine release, reducing interventions with higher doses of anti-inflammatory 
drugs or even halting their administration [56].
In addition, it has been shown that other organs display a cholinergic control of inflamma-
tion, such as gut, kidney, and liver. Despite lung exhibiting vagal innervation, activation of 
the cholinergic anti-inflammatory pathway is not sufficient to regulate inflammation; how-
ever, it is necessary to maintain the homeostasis. In this sense, vagus and/or splenic nerve 
stimulation appeared as an efficient procedure to minimize inflammation [57]. Furthermore, 
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in experimental glomerulonephritis, a genetic α7nAChR deletion exacerbates inflammation 
and fibrosis [6, 54]. Recently, Cedillo et al. showed that increased α7nAChR expression on 
peripheral blood mononuclear cells was associated with better control of inflammation, dis-
ease severity, and clinical outcome in septic patients and prognosis [58].
Concluding, both animal and human studies have suggested that the vagus nerve stimu-
lation has a potential protective regulating systemic inflammation in various pathologies, 
such as ischemia/reperfusion, sepsis, epilepsy, hemorrhagic shock, migraine, and others 
[13, 51, 59–61]. However, additional studies are needed to determine the interplay between 
the vagus and the splenic nerves, and their respective roles in modulating inflammation [6, 
12]. According to Martelli et al., several treatments are currently undergoing development, 
based on the cholinergic anti-inflammatory pathway [46].
3. Autonomic function and sepsis
Sepsis is an important cause of admission in intensive care units (ICU) and remains a 
major clinical and scientific challenge in modern medicine [53]; this is a huge and expen-
sive medical problem throughout the world, with a mortality rate ranging between 30 
and 50% [10, 62]. It is defined as life-threatening acute organ dysfunction, secondary to 
infection [63], characterized by abnormal body temperature, mental confusion, hypoten-
sion, diminished urine output, or thrombocytopenia [53, 63]. Over the past two and a half 
decades, there has been a tremendous effort to develop standardized diagnostic defini-
tions of sepsis, as described in (Table 1). The most prevalent sites of infection, responsible 
to trigger sepsis in humans, are the lungs, abdominal cavity, urinary tract, and primary 
infections of the blood stream. After the unsuccessful treatment of sepsis, the patient may 
develop circulatory, cellular, and metabolic abnormalities, such as, respiratory or renal 
failure, changes in coagulation, and profound and unresponsive hypotension [53], as well 
as modifications in cardiovascular, autonomic, neurological, hormonal, metabolic and 
clotting systems [72, 73]. These marked alterations are characterized by septic shock, the 
leading causes of death in sepsis [63].
The pathophysiology of sepsis is characterized as a host reaction to infection that involves a 
balanced inflammatory response, critical to fight the infection, and an unregulated pro- and 
anti-inflammatory response to induce organ damage in the host [73]. Thereby, the immune 
response in sepsis results in the increased levels of cytokines, designated hyperinflammatory 
phase and subsequently evolves to hypoinflammatory phase (immune-suppressive function) 
[39], the latter being more destructive and aggressive than the initial infection [73]. This imbal-
ance is determined by several factors, such as pathogen virulence, bacterial (i.e., lipoteichoic 
acid and bacterial lipopolysaccharide—LPS) [74] and patient-related factors (i.e., genetic 
background, age, and comorbidities) [53], leading the immune system to detect PAMPs 
(including components of bacterial, fungal, and viral pathogens) and DAMPS (endogenous 
molecules released from damaged host cells, including ATP, mitochondrial DNA, and high 
mobility group box 1 or HMGB1) [75]. For transcription of type I interferons and proinflam-
matory cytokines (i.e., TNF-8, interleukin (IL)-1, and IL-6) initiation, both DAMPs and PAMPs 
activate innate immune and some epithelial cells through pattern recognition receptors on the 
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cell surface (toll-like receptors and C-type lectin receptors) or in the cytosol (NOD-like recep-
tors, RIG-I-like receptors) [76, 77]. In the case of bacterial infection, when a microbiological 
diagnosis is made, about half of the cases show that 60% are caused by Gram-negative and 
Gram-positive bacterium in the remaining cases [53, 62, 78]. Lipopolysaccharide (LPS) from 
Gram-negative bacteria (an example of a PAMP) reacts with toll-like receptor 4 (TLR4), caus-
ing phagocytic cells to robustly generate a variety of proinflammatory cytokines signaling, 
leading to systemic inflammatory response syndrome (SIRS) [10].
In sepsis, not only the response of immune cells is highly context dependent to stimuli, but 
also, the nervous system itself depends on the inflammatory context [10]. Several evidences 
demonstrate that immune and inflammatory responses are regulated by the autonomic ner-
vous system through PNS and SNS activities [8, 14]. Essentially, to inhibit the inflammatory 
cytokine production by innate immune cells in the spleen, gut, and other organ, the carotid 
body chemoreceptors, afferent sensory vagal fibers, and brain areas with a permeable blood 
barrier respond to local and systemic cytokines, signaling to brainstem nuclei, which in turn 
send vagal, cholinergic efferents to the periphery [10, 79]. After bacterial infection, one of the 
Sepsis definitions
Previous definitions [64–68]
Diagnosis Signs and symptoms
Systemic inflammatory 
response syndrome (SIRS)
Two of the following symptoms:
• Body temperature > 38 or < 36°C
• Heart rate > 90 beats/min
• Respiratory rate > 20 breaths/min or arterial CO
2
 < 32 mmHg
• White blood cell count >12.000/mm3, <4000/mm3 or > 10% immature forms
Sepsis SIRS and proven or suspected infection
Severe sepsis Sepsis in combination with multiple organ dysfunction (MODS).
Septic shock Sepsis and persistent hypotension (mean arterial pressure [MAP] <65 mmHg) after 
fluid resuscitation and/or lactate >4 mmol
(36 mg/dL)
Revised definitions [63, 69, 70]
Diagnosis Signs
Sepsis • Life-threatening organ dysfunction caused by a dysregulated host response to 
infection
• Suspected or documented infection and an acute increase of >2 sequential (sepsis 
related) organ failure assessment (SOFA) points (SOFA score [71] is a proxy for 
organ dysfunction)
Septic shock • Septic shock is a subset of sepsis in which underlying circulatory and cellular/
metabolic abnormalities are profound enough to substantially increase mortality
• Sepsis and vasopressor therapy needed to increase MAP ≥65 mmHg and lactate 
>2 mmol/L (18 mg/dL) despite adequate fluid resuscitation
Table 1. Sepsis: previous and revised definition.
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first and local responses is the release of vasoactive peptides by spinal afferent C-fibers and 
the ensuing neurogenic inflammation. Vagal afferent C-fibers can exert neurogenic inflamma-
tory reflex actions, like those underlying some forms of diarrhea; however, in the proposed 
vagal anti-inflammatory reflex, the exact role of efferent parasympathetic vagal fibers remains 
to be elucidated, as these fibers do not seem to directly innervate the major immune organs 
[79, 80]. The work developed by Tracey and colleagues have shown that, in animal mod-
els of sepsis and in another inflammatory conditions (e.g., colitis, hemorrhagic shock, and 
ischemia-reperfusion injury), neural reflex involving the vagus nerve causes T cells to release 
acetylcholine and, therefore, interacts with the α7nAch receptor on macrophages to dampen 
the release of powerful proinflammatory mediators such as TNF-α and HMGB-1 [49, 50, 81]. 
In an animal model of cecal ligation puncture (CLP), improvements in survival and suppres-
sion of the SIRS response of sepsis were described after stimulation of the vagal nerve [81], as 
does the use of a selective or a universal synthetic agonist for α7nAchR on macrophages [49]. 
Another recent work indicates that vagal stimulation also reduces symptoms and inflamma-
tion in patients suffering from rheumatoid arthritis and Crohn’s disease [80].
Contrary to the lack of information on vagal innervation of immune organs and cells, there 
is longstanding evidence in favor of sympathetic nervous system innervation of primary 
and secondary immune organs (including, thymus, spleen, bone marrow, and lymph nodes) 
[82]. Depending on the kind of bacterial infection, there are different effects of SNS on bacte-
rial dissemination, innate immune cell responses, and inflammatory mediators [83]. During 
septic systemic inflammation, noradrenaline increases in immune organs where it can act 
on α and β receptors present on macrophages, and adrenaline release into the blood also 
increases, implying that almost any tissue macrophage could be exposed to adrenaline, which 
has been shown to modulate pro-inflammatory cytokine secretion by cultured blood cells 
[81]. Noradrenaline, which is both released and often administered during sepsis [84], may, 
along with adrenaline, exert pro-inflammatory actions through stimulation of β1 adrenergic 
receptors, as antagonists of this receptor have been shown to exert anti-inflammatory effects 
in experimental sepsis [85].
These findings show a specific interest, since, in clinical severe sepsis and septic shock, the 
selective β1 receptor blocker, esmolol, has shown beneficial effects on microcirculation and 
myocardial oxygen [84, 85]. Interestingly, in a rat model of CLP, esmolol has similar beneficial 
effects on vascular and cardiac function [86], and at the same time, it increases anti-inflammatory 
and reduces pro-inflammatory cytokine production, reduces bacterial component, and improves 
gut barrier function, ultimately increasing animal survival rates [87]. Although the SNS can 
influence infection-induced immune responses, depending on the type of bacteria and the 
timing of treatment, this kind of adrenergic drugs may have beneficial or detrimental effects 
on the active molecules. Notwithstanding, the promising anti-inflammatory effects of the β1 
antagonist esmolol need to be confirmed in clinical trials on septic patients [80].
4. Autonomic modulation and therapeutics in sepsis
Several advancements have been made over time to understand the neuroimmune mechanisms 
for maintaining and restoring homeostasis during normal and pathophysiologic conditions. 
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Some studies have already reported that, in adverse conditions, basic reflex mechanisms respond 
through efferent vagal and sympathetic circuits and that neurotransmitters influence leukocytes 
with important clinical implications [8, 43, 88]. In this heading, we will review the most relevant 
therapies associated with autonomic modulation, developed and tested over the last 3 years.
Regarding the importance of sympathetic downstream signaling in anti-inflammation pro-
cesses, one promising pharmacological approach is the inhibition of phosphodiesterase 4 
(PDE4), an enzyme that degrades cAMP [89]. It is reported that, by inhibiting this enzyme, 
the cAMP increases, and, consequently, shows promising results in several diseases, as pso-
riatic arthritis, rheumatoid arthritis, Behçet’s syndrome [90], and sepsis [91]. Focusing on 
sepsis studies, inhibitors of PDE4 reduce systemic vascular resistance and improve cardiac 
contractility and renal function [91]. PDE4 inhibitors also have a potent anti-inflammatory 
activity effect, by reducing microvascular leakage, all of which could be beneficial in infants 
with severe sepsis [92]. Table 2 summarizes the main treatments developed in the last 3 years 
based on pharmacologic PDE inhibition in sepsis.
It is known that studies in humans have their limitations and confounding variables, such as, 
differences between groups in age and sex, body mass index, disease severity, smoking, frailty, 
and physical activity [97]. However, interestingly, clinical responses could be attained through 
autonomic nervous system modulation, as well as pro- and anti-inflammatory interventions 
[6, 98]. Several approaches, such as lifestyle interventions, medications, and devices, could 
be repurposed or further expanded to target inflammation. For example, to lessen systemic 
inflammation, in metabolic and cardiovascular diseases, it is necessary to develop measures 
to attenuate sympathetic activity [6, 98, 99]. Similarly, observations in animal models showed 
that sympathetic inhibition could improve the immunosuppression associated with strokes, 
and thereby, prevent infectious complications and deaths [6]. At the moment, there are some 
clinical trials in progress, to evaluate the effects of the cholinergic anti-inflammatory pathway 
by vagus nerve stimulation in patients with sepsis, severe sepsis, and shock septic, but there 
are also, at least, five clinical trials that are evaluating the oxytocin in endotoxemia model 
(https://clinicaltrials.gov/ct2/results?cond=Sepsis&term=esmolol&cntry=&state=&city=&dist).
Taking into account the cholinergic anti-inflammatory pathway, the major discoveries have 
been associated with: vagus nerve stimulation (VNS) and transvenous vagus nerve stimu-
lation (tVNS) in anti-inflammatory responses, the identification of α7nAChRs in different 
cell types (macrophages, dendritic cells, and microglial cells) as targets for suppression of 
inflammation, and the integration of cholinergic T cells into the efferent neuroimmune path-
way within the spleen, and also, some pharmacological approaches [98]. Although the vagal 
neuroimmune pathway is still controversial in specific situations (e.g., sterile or pathogen-
induced inflammation), the effect of vagal stimulation could be beneficial to the host by 
inhibiting exacerbated cytokine production and inappropriate neutrophil entrapment into 
vital organs [12, 16]. By contrast, the cholinergic anti-inflammatory pathway can inhibit spe-
cific innate immune responses that are crucial to eliminate the bacteria (e.g., initial neutrophil 
migration) and subsequently increase the mortality in sepsis [100, 101]. Nevertheless, while 
VNS will unlikely replace the standard intensive care therapy, it is quite possible that, in 
the future, autonomic modulation through VNS would become an adjunct to benefit septic 
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Pharmacological approach
Target Study Method Conclusions Perspectives Year
Dibutyryl-
cAMP
Rolipram
Roflumilast
Inhibition of 
phosphodiesterase 4B 
(PDE4)
In vitro: 
macrophage cell 
line (mouse)
Animal (mice)
Cell: LPS
(10 ng/ml)
Mice: LPS 
(10 mg/kg)
Upregulates anti-inflammatory 
cytokine IL-1Ra production in 
vitro and in vivo
PDE4B-selective inhibitors may retain 
the anti-inflammatory effects of 
nonselective PDE4 inhibitors
2017 
[93]
Roflumilast Effects on a CLP-model-
induced sepsis
Animal (mice) CLP Reduce of bacterial load
Inhibition of the IL-6 and TNFα 
expression
Alleviation of liver injury
May be an appropriate treatment of 
sepsis
Needed more studies.
2017 
[94]
Rolipram
Azithromycin
Ethyl 
pyruvate
Metformin
Investigate potential 
antiendotoxic effects
In vitro (cells of 
horses)
LPS (1 μg/
ml)
Rolipram: the most potent 
inhibitor of cytokine production
Further work is required to investigate 
the potential use in vivo.
2015 
[95]
Rolipram Impact of the PDE4 
inhibition on hepatic 
integrity
Animal (rat) LPS 
(2.5 mg/kg, 
i.v.)
Improvement of hepatic 
microcirculation and integrity
Protective effect on hepatoma cell 
line viability
Further studies needed to determine 
clinical applicability of PD-4-I
2015 
[96]
Table 2. Pharmacologic phosphodiesterase (PDEs) inhibition in sepsis disease.
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Target Study Method Conclusions Perspectives Year
Autonomic modulation
Chemoreflex 
stimulation
and 
pharmacological 
intervention
Chemoreflex activation
Pharmacological 
blockade
(methylatropine or 
propranolol)
Animal (rat) LPS
(1.5 mg/kg, i.v.)
Attenuates the use of TNFα, IL- 
1β, and IL-6 plasma levels
Increases the IL-10 plasma levels
Methods to stimulate CSN, which is a 
promising therapeutic strategy
2017
[102]
Vagal nerve 
stimulation
B(VNS)
Assessed changes in 
IL-6 and TNFα
Animal
(rat)
LPS
(0.5 mg/kg, 
intratracheally)
Attenuates the upregulation of 
IL-6 and TNFα
Viable alternative to antibiotics
Provides a suggestive link between 
VNS and potential clinical 
application to treat sepsis in preterm 
infants
2016
[103]
Effects on 
sepsis-associated 
encephalopathy
Animal (rat) LPS (i.v.) Activates anti-inflammatory 
effect through cholinergic 
pathway
Improves the cerebral function
Reduces systemic and cerebral 
inflammatory reaction
Requires more research 2015
[104]
Potential role of 
prostaglandin 
in cholinergic 
neuro-regulation
Animal (mice) LPS (2 mg/kg, 
i.p.)
VNS decreases the release of 
pro-inflammatory cytokines both 
in serum and spleen
Further development of therapeutic 
directed of inflammatory reflex 
modulation, and immunosuppression 
in chronic inflammatory diseases
2015
[105]
Transvenous 
vagus nerve 
stimulation (tVNS)
Determine the 
feasibility and safety, 
investigated its putative 
anti-inflammatory 
effects
Randomized 
double-blind 
study
LPS (2 ng/kg, 
i.v).
tVNS is feasible and safe but 
does not influence the systemic 
inflammatory response in vivo
Short-term tVNS does not modulate 
the innate immune response in 
humans
Require more studies
2015 
[106]
α7 gene expression 
level in peripheral 
blood mononuclear 
cells (PBMC) as marker 
for CAP
Pilot study Septic patients 
within the 
first 24 hours 
of diagnosing 
sepsis
PBMC α7 gene expression level 
is a clinically relevant marker for 
CAP activity in sepsis: the higher 
the α7 expression, the better the 
inflammation control and the 
prognosis
The CAP activation in high-risk 
septic patients has therapeutic 
potential: this activation could be 
used as an adjunctive therapy
2015[58]
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Target Study Method Conclusions Perspectives Year
Pharmacological intervention
Esmolol Effects on reducing 
apoptosis and 
inflammation
Animal (rat) CLP Reduces apoptosis and 
inflammatory reaction and protect 
key organs
Needed clinical trials to confirm the 
use of esmolol in sepsis treatment
2017 
[87]
Effect on tissue 
perfusion and the 
clinical prognosis of 
patients with severe 
sepsis
Prospective 
cohort clinical 
trial
Continuous 
infusion of 
esmolol via 
central venous 
catheter
Controlled heart rate reduced the 
duration of mechanical ventilation
No significant effects on 
circulatory or tissue perfusion
Requires further research. 2016 
[84]
Effects on myocardial 
and vascular function
Animal (rat) CLP Enhances intrinsic cardiac 
contractility and improves 
vascular responsiveness to 
catecholamines
Further investigation needed to 
determine the effects of β1-blockade 
on other organ functions and 
inflammatory patterns in septic shock.
2015 
[86]
Oxytocin Effects on the 
cardiorespiratory 
activity
Animal (rat) LPS (0.1 mg/kg; 
intraperitoneally)
Potential cardioprotective peptide
Diminished tachypnea and restore 
the cardiorespiratory interactions
Provokes a less anticorrelated 
pattern in HRV
Decreased mean heart rate
Reduce lethargy and moderated 
the hyperthermia
These findings confirm the suitability 
of the electrocardiogram-derived 
respiration technique to obtain the 
estimated respiration signal in rodent 
models
2017 
[107]
2016 
[108]
Xanomeline Effect on brain 
muscarinic acetylcholine 
receptor (mAChR)-
mediated cholinergic 
signaling
Animal (mice, 
rat)
LPS (6 mg/kg, i.p)
CLP
Suppresses serum and splenic 
TNF levels
Alleviates sickness behavior, and 
increased survival
Further studies centrally-acting M1 
mAChR agonists as experimental 
therapeutic agents in a broader 
spectrum of inflammatory conditions
2015 
[109]
Other
ANS indices Investigate how changes 
in cardiovascular 
indices can be a sign of 
progression of organ 
failure
Prospective 
observational 
cohort study
Follow-up during 
the first 3 days 
of ICU stay after 
development of 
septic shock
Variability of heart rate 
significantly increases in septic 
shock patients presenting 
improvement of organ function 
from ICU day 1 to day 3.
Further investigations are required to 
find specific associations with drug 
dosage, namely, drugs acting on the 
sympathetic system, and clinically 
relevant outcomes
2017 
[110]
Table 3. Sepsis: autonomic modulation, therapeutics, and treatments based on the PNS therapy.
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patients [100, 101]. The most relevant treatments and therapies based on parasympathetic 
nervous system developed over the last 3 years, in animal models and human studies, are 
shown in Table 3.
5. Conclusion
The nervous and immune systems are not fully independent. When the body is inflamed, both 
systems produce neurotransmitters and cytokines and express receptors that are involved in 
important physiological functions and in the maintenance of homeostasis. The reactions of the 
immune competent cells to neurotransmitters are variable, depending on the context of receptor 
engagement, such as, activation state of the cell, expression pattern of neurotransmitter recep-
tors, microenvironment, cytokine, and distance from the catecholamine source (concentration). 
It is already well described that autonomic modulation in acute and chronic inflammation has 
been implicated with a sympathetic interference in the earlier stages of the inflammatory pro-
cess and the activation of the vagal inflammatory reflex to regulate innate immune responses 
and cytokine functional effects in longer more chronic processes. The present chapter reviewed 
the overall autonomic mechanisms controlling inflammatory responses in several conditions 
such as, burn processes, arthritis rheumatoid, obesity, with a special focus on the inflammatory 
processes associated with sepsis. Furthermore, the most relevant therapeutic options for the 
latter, through autonomic modulation, were also reviewed and summarized.
In summary, it is quite clear that sepsis remains a worldwide clinical challenge and therapies’ 
outcomes depend largely on host factors. Henceforth, continuous searching for new and more 
effective therapies during the initial phases of sepsis is utterly important, in order to reduce 
the mortality associated with this syndrome (condition).
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